Halozyme Therapeutics Inc (HALO)

[rod5247]

Overview of key presentations featuring Roche medicines


Medicine

Description of study

Abstract number



ACE910 (RG6013)

(investigational)
Safety and Prophylactic Efficacy Profiles of ACE910, a Humanized Bispecific Antibody Mimicking the FVIII Cofactor Function, in Japanese Hemophilia A Patients Both without and with FVIII inhibitors: First-in-Patient Phase 1 Study
Abstract

#691

Gazyva/Gazyvaro (investigational use) Obinutuzumab (GA101) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or bendamustine for the first-line treatment of follicular NHL: final results from the maintenance phase of the phase Ib GAUDI study
Abstract

#1743

Gazyva/Gazyvaro (investigational use) Preliminary safety results from the phase IIIb GREEN study of obinutuzumab (GA101) alone or in combination with chemotherapy for previously untreated or R/R CLL
Abstract

#3345

Gazyva/Gazyvaro (investigational use) A phase Ib study of obinutuzumab combined with lenalidomide for relapsed/refractory follicular B-cell lymphoma
Abstract

#4458

MabThera/Rituxan (investigational use) Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): a review of response of two phase III studies of the German CLL Study Group (GCLLSG)
Abstract

#23


MabThera

(investigational use)
Non-inferior pharmacokinetics (PK) and comparable safety and response rates for subcutaneous (SC), compared with intravenous (IV), rituximab in combination with fludarabine and cyclophosphamide (FC) in patients (Pts) with untreated CLL: part 2 of the phase Ib SAWYER study (BO25341)
Abstract

#1995

Polatuzumab vedotin (investigational) Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma
Abstract

#4457


RG7388

(investigational)
Phase 1/1b study of RG7388, a potent MDM2 antagonist, in acute myelogenous leukemia (AML) patients (pts)
Abstract

#116

Venetoclax (investigational) A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
Abstract

#118

Venetoclax (investigational) Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Abstract

#325

Venetoclax (investigational) The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma
Abstract

#1722

Venetoclax (investigational) Preliminary Results of a Phase 1b Study (GO28440) Combining GDC-0199 (ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
Abstract

#3337

Venetoclax (investigational) Preliminary results of a phase 1b study (GP28331) combining GDC-0199 (ABT-199) and obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL)
Abstract

#4687

Look at how many of what Roche identifies as "key presentations" at ASH 2014 include MabThera/Rituximab.